Cargando…

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma

OBJECTIVES: Our aim was to describe our experience in using apatinib as treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC). METHODS: Forty-seven patients undergoing apatinib treatment for RAIR-DTC were prospectively enrolled in this study. The study endpoints were objec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Wei, Shi, Xiangyu, Fang, Qigen, Zhang, Xu, Liu, Shanting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904562/ https://www.ncbi.nlm.nih.gov/pubmed/35282451 http://dx.doi.org/10.3389/fendo.2022.768028

Ejemplares similares

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
por: Qiu, Xian, et al.
Publicado: (2022)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer
por: Lin, Yansong, et al.
Publicado: (2017)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
por: Meng, Chao, et al.
Publicado: (2023)

Lateral Lymph Node Metastases in T1a Papillary Thyroid Carcinoma: Stratification by Tumor Location and Size
por: Zhang, Xiaojun, et al.
Publicado: (2021)

Corrigendum: Lateral Lymph Node Metastases in T1a Papillary Thyroid Carcinoma: Stratification by Tumor Location and Size
por: Zhang, Xiaojun, et al.
Publicado: (2022)

Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2021)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Metastasis of cN0 Papillary Thyroid Carcinoma of the Isthmus to the Lymph Node Posterior to the Right Recurrent Laryngeal Nerve
por: Du, Wei, et al.
Publicado: (2021)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy
por: Wang, Congcong, et al.
Publicado: (2023)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Feasibility of Submandibular Gland Preservation in cT1-2N0 Squamous Cell Carcinoma in the Floor of the Mouth
por: Du, Wei, et al.
Publicado: (2020)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Predictors of Malignancy in Thyroid Nodules Classified as Bethesda Category III
por: Liu, Xiaoli, et al.
Publicado: (2022)

Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult
por: Zhao, Xianlan, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

The association between the interval of radioiodine treatment and treatment response, and side effects in patients with lung metastases from differentiated thyroid cancer
por: Wang, Hongxi, et al.
Publicado: (2023)

Ultrasound-guided implantation of radioactive (125)I seed in radioiodine refractory differentiated thyroid carcinoma
por: Chen, Wei, et al.
Publicado: (2021)

Fine Needle Biopsy Versus Core Needle Biopsy Combined With/Without Thyroglobulin or BRAF 600E Mutation Assessment for Detecting Cervical Nodal Metastasis of Papillary Thyroid Carcinoma
por: Zhang, Xiaojun, et al.
Publicado: (2021)

Weathering the Storm: Thyroid Storm Precipitated by Radioiodine Contrast in Metastatic Thyroid Carcinoma
por: Basida, Brinda, et al.
Publicado: (2021)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
por: Sa, Ri, et al.
Publicado: (2020)

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
por: Yu, Feng, et al.
Publicado: (2021)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?
por: Jiang, Yongji, et al.
Publicado: (2023)

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review
por: Li, Jiayi, et al.
Publicado: (2022)

A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: (125)I Seed Implantation Plus Apatinib After Surgery
por: Niu, Yiqi, et al.
Publicado: (2020)

Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials
por: Auttara-atthakorn, Arunrat, et al.
Publicado: (2022)

GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy
por: Barros-Filho, Mateus C., et al.
Publicado: (2020)

Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
por: Samimi, Hilda, et al.
Publicado: (2022)

Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
por: Jiang, He-Jiun, et al.
Publicado: (2021)

Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients
por: Drozd, Valentina, et al.
Publicado: (2020)

Randomized Clinical Trial: Probiotics Alleviated Oral-Gut Microbiota Dysbiosis and Thyroid Hormone Withdrawal-Related Complications in Thyroid Cancer Patients Before Radioiodine Therapy Following Thyroidectomy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma
por: Li, Genpeng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kervvcr6lmf3pf76v6tands3gh